Microbiome

Microbiome patterns in this study were linked to inflammation (fecal calprotectin) and higher chance of needing treatment escalation. If validated, enterotype stratification could help predict disease course or tailor...

The review links TCM-derived compounds to mechanisms (microbiota, metabolites, immunity) that are implicated in progression from chronic colitis to colorectal cancer, which is an important long-term risk for people with...

Diet is a potentially modifiable factor that could affect symptoms, inflammation, and the gut microbiome in ulcerative colitis; this trial aims to test whether a modified Mediterranean diet added to standard therapy...

Preclinical work identifies a natural-product mixture that reduced inflammation, improved gut barrier markers, and changed the microbiome in a mouse model of ulcerative colitis. This could be an early step toward new...

The study suggests IBD patients can fall into two distinct gut-microbe/metabolite types that align with differences in disease severity and mental-health scores, which could help explain why patients with the same...

The study suggests a new microbiota–metabolite–immune pathway (palmitic acid → PI3K/AKT → NETs) that may drive colitis and that Forsythia polysaccharides can modify, which could point to future microbiota-targeted...

The paper describes a novel colon-targeted delivery system that improved local drug retention, reduced dosing frequency, and changed microbiota and metabolic markers in a mouse model of UC — developments that could...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Gut Pathogens.

Crohn's is becoming more common among younger Americans and long-term uncontrolled inflammation raises colorectal cancer risk. Understanding possible lifestyle and medical factors can help patients and clinicians focus...

People with IBD are at increased risk of bone loss; this study points to a microbiome-related pathway (A. muciniphila and an IDA metabolite) that might protect bone in an experimental colitis model, which could...

The study describes a new nanozyme-based oral formulation that reduced NET formation and improved mucosal healing in a mouse model of ulcerative colitis, suggesting a novel preclinical approach to long‑term...

Nanozyme-based therapeutics are an emerging experimental strategy that aim to reduce oxidative stress and modulate immune responses in the inflamed gut — mechanisms directly relevant to IBD pathophysiology.

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from AMB Express.

Researchers report that a polysaccharide from Radix Hedysari reduced inflammation, improved barrier proteins, and shifted gut bacteria in a mouse model of ulcerative colitis — suggesting a potential preventive candidate...

Researchers are developing oral delivery methods to make promising anti‑inflammatory compounds more effective. If such platforms translate to humans, they could expand treatment options for UC by improving absorption of...

The paper identifies a specific probiotic strain that reduced colitis signs and improved intestinal barrier function in a mouse model, supporting further preclinical and translational work toward microbiome-based...

IBD patients often have depression and anxiety that current anti-TNF biologics do not adequately treat. An engineered probiotic that both neutralizes local TNFα and promotes GABA-producing microbes could address...

This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...

People with Crohn's disease often ask whether food additives and artificial sweeteners affect gut microbes or disease activity. This trial directly tests whether sucralose changes the fecal microbiome in adults with...

If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.

Parents and clinicians often worry that when solids are started might change a child’s future risk of IBD. This large prospective study found no clear link between timing or patterns of complementary feeding and later...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Journal of Drug Delivery Science and...

FMT is an active area of research that could affect future IBD treatments; patients with IBD commonly experience obesity and complex care decisions. Updates on FDA-approved FMT products and ongoing Crohn’s studies may...

The study shows functional differences in how Crohn’s versus healthy fecal microbiota ferment substrates, with CD cultures making less beneficial butyrate and more ethanol/amino acids. That could inform future...

A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...

IBD and obstructive sleep apnea may influence each other through shared biological processes (barrier dysfunction, dysbiosis, immune activation, intermittent hypoxia), so understanding this could affect screening and...

Viruses in the gut (including bacteriophages) could influence inflammation and the intestinal barrier in IBD, so understanding the virome may point to new research directions or therapies.

The work suggests specific host genes and cell types that might mediate links between gut microbes and IBD, which could direct future laboratory research into mechanisms and potential biomarkers.

The study reports that Chlorella-derived polysaccharide AHP reduced inflammation, supported barrier repair, and changed gut microbiota in cell and mouse colitis models—suggesting a potential new bioactive candidate for...

Nanoencapsulated flavonoids are proposed as a way to improve delivery of biologically active dietary compounds to the inflamed gut in IBD; a rational design framework could accelerate translation from bench research to...

Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...

The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...

This preclinical study suggests a heat‑inactivated probiotic strain reduced colitis signs in mice and changed gut microbes and inflammatory pathways—findings that could inform future research into microbiome‑based or...

Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...

The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...

This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...

m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...

This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...

This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.

Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...

This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...

This study suggests a specific four-strain probiotic cocktail may better protect against experimental colitis than the three-strain mix, potentially via microbiota-driven increases in spermidine — a microbial metabolite...

People with ulcerative colitis may be interested in plant-based therapies that could reduce gut inflammation or support mucosal health. This review compiles preclinical evidence suggesting Terminalia arjuna has...

This review highlights a plant-derived compound, ferulic acid, that showed anti-colitis effects in experimental studies, suggesting a potential new adjunctive therapy pathway worth watching for future clinical research.

If true, prenatal and early-life exposures could influence long-term IBD risk by shaping immune development and the gut microbiome, which may help explain why some people develop IBD and others don’t.

Diet is a modifiable factor many people with IBD try to use to manage symptoms and disease; this review summarizes what is and isn’t supported by current evidence for popular diets and structured nutritional therapies.

The review highlights marine polysaccharides as multi-target agents that could modulate inflammation, the microbiome, and the gut barrier—processes central to ulcerative colitis—and points to possible roles as functional...